Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

421. Cohort study: Long-term aspirin use and neovascular age-related macular degeneration: association or causation?

Cohort study: Long-term aspirin use and neovascular age-related macular degeneration: association or causation? Long-term aspirin use and neovascular age-related macular degeneration: association or causation? | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-term aspirin use and neovascular age-related macular degeneration: association or causation? Article Text Aetiology Cohort study Long-term aspirin use and neovascular age

2014 Evidence-Based Medicine

422. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication

aspirin use to reduce the risk for preeclampsia, preterm birth, and intrauterine growth restriction in women at high risk for preeclampsia. Other Relevant USPSTF Recommendations The USPSTF recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid. These recommendations are available at . For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting (...) -eclampsia and its complications. Cochrane Database Syst Rev . 2007;(2):CD004659. 11. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet . 2007;369:1791-8. 12. Jensen MS, Rebordosa C, Thulstrup AM, Toft G, Sørensen HT, Bonde JP, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. Epidemiology . 2010;21(6):779

2014 U.S. Preventive Services Task Force

423. Safety of renal biopsy for patients taking aspirin

Safety of renal biopsy for patients taking aspirin Safety of renal biopsy for patients taking aspirin Safety of renal biopsy for patients taking aspirin Mitchell MD, Berns JS, Rudnick MR, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Berns JS, Rudnick MR, Umscheid CA. Safety of renal biopsy for patients taking (...) aspirin. Philadelphia: Center for Evidence-based Practice (CEP). 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Aspirin; Biopsy; Humans; Nephrectomy; Platelet Aggregation Inhibitors Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2

2014 Health Technology Assessment (HTA) Database.

424. Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence

. Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Two systematic reviews, two randomized controlled trials, and two non-randomized studies were identified regarding the use of acetylsalicylic acid (ASA) for venous thromboembolism (VTE) prophylaxis in patients undergoing total hip or total knee replacement. Final publication URL Indexing Status Subject (...) Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH

2014 Health Technology Assessment (HTA) Database.

425. Safety and Efficacy of Warfarin plus Aspirin Combination Therapy for Giant Coronary Artery Aneurysm Secondary to Kawasaki Disease: A Meta-Analysis. (Abstract)

Safety and Efficacy of Warfarin plus Aspirin Combination Therapy for Giant Coronary Artery Aneurysm Secondary to Kawasaki Disease: A Meta-Analysis. To compare the safety and efficacy of warfarin plus aspirin versus aspirin alone for the treatment of children with giant coronary artery aneurysm (CAA) secondary to Kawasaki disease (KD).We searched the PubMed, EMBASE, Cochrane Library, CNKI, WANFAN and VIP databases. We selected case-controlled trials of warfarin plus aspirin versus aspirin alone (...) for the treatment of children with giant CAA secondary to KD.Six retrospective studies met our inclusion criteria. There was no significant difference between the warfarin plus aspirin and aspirin alone groups in the rate of CAA regression (OR 1.38, 95% CI 0.52-3.68, p = 0.52) or the incidence of persistent CAA (OR 2.34, 95% CI 0.16-33.50, p = 0.53), coronary artery stenosis (OR 0.55, 95% CI 0.18-1.72, p = 0.30) or thrombus formation (OR 0.50, 95% CI 0.15-1.69, p = 0.26). There was evidence that warfarin plus

2014 Cardiology

426. Efficacy and Safety of Adding Clopidogrel to Aspirin on Stroke Prevention among High Vascular Risk Patients: A Meta-Analysis of Randomized Controlled Trials. (Full text)

Efficacy and Safety of Adding Clopidogrel to Aspirin on Stroke Prevention among High Vascular Risk Patients: A Meta-Analysis of Randomized Controlled Trials. Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to assess the efficacy and safety of adding clopidogrel to aspirin on stroke prevention in high vascular risk patients, and to provide evidence for a suitable duration of dual (...) antiplatelet therapy.We searched PubMed, EMBase, OVID and Cochrane Central Register of Controlled Trials (up to June, 2013) for randomized controlled trials evaluating the efficacy and safety of clopidogrel plus aspirin versus aspirin alone in high vascular risk patients. Comparisons of stroke and hemorrhagic complications between treatment groups were expressed by the pooled Relative Risks (RRs) with 95% Confidence Intervals (CIs).Fifteen trials with a total of 97692 intention-to-treat participants were

2014 PloS one PubMed abstract

427. The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis. (Abstract)

The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis. The role of aspirin use in chemoprevention of esophageal adenocarcinoma (EAC) is still unclear. Previous meta-analyses have reported a beneficial effect of aspirin use, whereas it remains still under debate whether there are non-linear frequency-risk and duration-risk relations, such as a "threshold" effect.Nine observational studies reporting the association between (...) aspirin use and EAC risk were selected through a combined search with the PUBMED and EMBASE electronic databases of articles published before June 2013. Overall odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed-effects models, and the cubic spline regression models were performed for the study of frequency-risk and duration-risk relations.A monotonically decreasing relation was observed only for ≤ 4.5 times per week (OR=0.75, 95%CI 0.64-0.88, for twice per week; OR=0.59

2014 Pharmacoepidemiology and drug safety

428. Safety and efficacy outcomes of preoperative aspirin in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis. (Abstract)

Safety and efficacy outcomes of preoperative aspirin in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis. The administration of aspirin is traditionally discontinued prior to coronary artery bypass grafting (CABG), given a potential risk of excessive postoperative bleeding. Few studies have previously suggested the benefits of continuing aspirin until the time of surgery. The primary aim of this review is to evaluate the effects of preoperative aspirin (...) therapy on several clinically important outcomes in patients undergoing CABG.A meta-analysis of eligible studies of patients undergoing CABG, reporting preoperative aspirin in comparison with no aspirin/placebo and our outcomes, was carried out. The safety outcomes included postoperative bleeding, packed red blood cell (PRBC) transfusion requirements, and reoperation for bleeding. The efficacy outcomes included perioperative myocardial infarction (MI), cerebrovascular accidents (CVAs

2014 Journal of cardiovascular pharmacology and therapeutics

429. High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. (Abstract)

High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. The aim of this study was to analyze the association between aspirin intake and its effect for chemoprevention of pancreatic cancer incidence by using a meta-analysis method.The databases of MEDLINE, EMBASE, and Wangfang (Chinese database) were retrieved to identify eligible studies. Odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effects (...) model.A total of 10 studies (4 case-control studies, 5 prospective cohort studies, and 1 randomized controlled trial) with 7,252 cases of pancreatic cancer and more than 120,0000 healthy control subjects were enrolled in the studies. Pooled analyses showed that high-dose aspirin intake was marginally associated with decreased risk for pancreatic cancer for overall analysis (OR, 0.88; 95% CI, 0.76-1.01) as well as for both cohort and case-control studies (OR, 0.70; 95% CI, 0.54-1.16, for the cohort

2014 Pancreas

430. Chinese herbal medicine for aspirin resistance: a systematic review of randomized controlled trials. (Full text)

Chinese herbal medicine for aspirin resistance: a systematic review of randomized controlled trials. Aspirin resistance (AR) is a prevalent phenomenon and leads to significant clinical consequences, but the current evidence for effective interventional strategy is insufficient. The objective of this systematic review is thus to assess the efficacy and safety of Chinese herbal medicine (CHM) for AR. A systematical literature search was conducted in 6 databases until December 2012 to identify

2014 Evidence-based Complementary and Alternative Medicine (eCAM) PubMed abstract

431. Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. (Abstract)

Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. 22269629 2012 03 13 2018 12 01 1555-7162 125 2 2012 Feb The American journal of medicine Am. J. Med. Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. e13 10.1016/j.amjmed.2011.08.027 Cleland John G F JG eng Letter Comment United States Am J Med 0267200 0002-9343 0 Cardiovascular Agents R16CO5Y76E Aspirin AIM IM (...) Am J Med. 2011 Jul;124(7):621-9 21592450 Aspirin pharmacology Cardiovascular Agents pharmacology Cause of Death Female Humans Male Myocardial Infarction epidemiology prevention & control Primary Prevention methods Stroke epidemiology prevention & control 2011 07 25 2011 08 15 2011 08 15 2012 1 25 6 0 2012 1 25 6 0 2012 3 14 6 0 ppublish 22269629 S0002-9343(11)00831-X 10.1016/j.amjmed.2011.08.027

2013 The American journal of medicine

432. Aspirin for the prevention of cardiovascular morbidity. (Abstract)

Aspirin for the prevention of cardiovascular morbidity. Aspirin (ASA) use for secondary prevention in patients with cardiovascular (CV) disease is well established through its beneficial effects on the reduction of myocardial infarction, ischemic stroke and CV mortality. This beneficial effect of ASA seems to consistently outweigh the risk in most patient subsets. Current guidelines endorse ASA for primary prevention of CV events in adults who are at moderate-high risk of CV morbidity. Recent (...) emerging data on the efficacy and safety of ASA conflicts with former randomized clinical trials and raises concerns regarding the validity of these recommendations. The following manuscript describes the data emerging from contemporary trials regarding the efficacy and safety of ASA in various patient subsets. The authors propose certain strategies to enhance safety and efficacy in order to augment the beneficial effects of ASA along with other modalities of primary prevention for suitable candidates

2013 Minerva medica

433. Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. (Abstract)

Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. It was hypothesized that low-dose aspirin could improve implantation rates in subsequent pregnancies in women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). Previous studies have shown inconclusive results or focused on surrogate endpoints. We therefore conducted a systematic review and meta-analysis of the literature (...) investigating the effect of low-dose aspirin on hard outcomes, including live birth rate, pregnancy rate and miscarriage.MEDLINE and EMBASE databases were searched up to November 2011. Randomized controlled trials comparing low-dose aspirin with placebo/no treatment in IVF/ICSI women were included. Pooled odds ratios (ORs) and 95%confidence intervals (CIs) were calculated.Seventeen studies with 6403 patients were included. The use of aspirin did not improve live birth pregnancy rate compared with placebo

2013 Journal of thrombosis and haemostasis : JTH

434. Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. (Abstract)

Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. Aspirin has been reported to be less effective for secondary vascular prevention in patients with ischaemic stroke, compared with other high-risk populations. This contention is largely based on results of meta-analyses that used a composite outcome of vascular death, myocardial infarction and stroke, reporting a 13% relative risk reduction. In this study, we explore whether the summary relative (...) risk reduction for this composite outcome is representative of estimates for each of the individual components of the composite.All randomised controlled trials comparing aspirin with placebo/control in patients following ischaemic stroke or transient ischaemic attack, beyond the acute period (2 weeks).A fixed-effects model was used and summary risk ratios were calculated for each of the outcomes: vascular mortality, recurrent non-fatal stroke, non-fatal myocardial infarction, composite

2013 Cerebrovascular diseases (Basel, Switzerland)

435. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. (Abstract)

Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. To compare the effect of early administration of aspirin on the risk of preterm and term preeclampsia.A systematic review and meta-analysis of randomized controlled trials were performed. Women who were randomized to low-dose aspirin or placebo/no treatment at or before 16 weeks of gestation were included. The outcomes of interest were preterm preeclampsia (...) (delivery <37 weeks) and term preeclampsia. Pooled relative risks (RR) with their 95% confidence intervals (CI) were computed.The search identified 7,941 citations but only five trials on a combined total of 556 women fulfilled the inclusion criteria. When compared to controls, aspirin initiated ≤16 weeks of gestation was associated with a major reduction of the risk of preterm preeclampsia (RR 0.11, 95% CI 0.04-0.33) but had no significant effect on term preeclampsia (RR 0.98, 95% CI 0.42-2.33).Low

2013 Fetal diagnosis and therapy

436. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. (Abstract)

Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. The use of low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes is recommended by existing guidelines, but definitive evidence supporting its efficacy is lacking. The authors undertook a meta-analysis of published trials to determine the effect of low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes.Randomized (...) controlled trials comparing low-dose aspirin versus placebo or no treatment in patients with diabetes (either exclusively or as a subgroup) with no previous history of cardiovascular disease were identified through MEDLINE and EMBASE databases.Seven randomized controlled trials met the inclusion criteria. Two studies included exclusively patients with diabetes, whereas the remaining 5 studies included patients with diabetes as a subgroup. Two studies were excluded because they did not provide diabetes

2013 The American journal of the medical sciences

437. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. (Abstract)

Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. We performed a meta-analysis of data from randomized trials to estimate the risk of all-cause mortality and bleeding (and especially gastrointestinal [GI] bleeding) in patients treated with low doses of acetylsalicylic acid (ASA) (75-325 mg/d), alone or in combination with other medications.We searched 10 electronic databases (until October 2010) and collected data on adverse events in randomized (...) . The risk of major GI bleeding increased with low doses of ASA alone (OR, 1.55; 95% CI, 1.27-1.90), compared with inert control reagents. The risk increased when ASA was combined with clopidogrel, compared with aspirin alone (OR, 1.86; 95% CI, 1.49-2.31), anticoagulants vs low doses of ASA alone (OR, 1.93; 95% CI, 1.42-2.61), or in studies that included patients with a history of GI bleeding or of longer duration. Importantly, PPI use reduced the risk for major GI bleeding in patients given low doses

2013 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

438. Aspirin desensitization for aspirin-exacerbated respiratory disease (Samter's Triad): a systematic review of the literature. (Abstract)

Aspirin desensitization for aspirin-exacerbated respiratory disease (Samter's Triad): a systematic review of the literature. To critically review the current literature regarding aspirin desensitization treatment for nasal polyposis in patients with Aspirin-Exacerbated Respiratory Disease (AERD).Systematic review of the literature.All English literature published between January 1995 and February 2013 reporting specifically nasal outcomes following aspirin desensitization in AERD patients were (...) improvement in symptom scores, decrease in corticosteroid use, and decrease in revision surgery. A few studies showed promising results with quantitative outcomes. However, most studies were of Level 2 evidence with small samples sizes. Rates of adverse events ranged from 12.5% to 23%.Unlike traditional treatments for nasal polyposis, aspirin desensitization targets AERD etiology rather than phenotype and can be an effective therapeutic option. While the current literature shows encouraging results

2013 International forum of allergy & rhinology

439. The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. (Full text)

The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. Evidence is mounting suggesting that a strong genetic component underlies aspirin insensitivity. To generate more information, we aimed to evaluate the association of four common polymorphisms (rs3842787, rs20417, rs201184269, rs1126643) from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity via a meta-analysis.In total (...) ) with aspirin insensitivity under allelic model. In subgroup analyses, the risk estimate for rs1126643 was greatly potentiated among patients with aspirin semi-resistance relative to those with aspirin resistance, especially under dominant model (aspirin semi-resistance: 5.44; 1.42-20.83; 0.013 versus aspirin resistance: 1.96; 1.07-3.6; 0.03). Further grouping articles by ethnicity observed a stronger prediction of all, but rs20417, examined polymorphisms for aspirin insensitivity in Chinese than

2013 PloS one PubMed abstract

440. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 Health Technology Assessment (HTA) Database.